Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

SelonabantAlso known as ANEB-001

CB1 antagonist in development for acute cannabinoid intoxication; it reduced THC effects in a phase II trial in healthy volunteers.

Level of detail

C₂₂H₂₄ClF₃N₂O₂

CAS 791848-71-0

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
440.90 g/mol

Updated on

In plain terms

Selonabant is an experimental molecule that blocks the CB1 receptor, the one THC activates. In a 2025 trial in healthy volunteers who had been given THC, it markedly reduced the feeling of being « high » and postural instability. It is not authorised as a medicine.

Receptors and activity

Target network

CB1Antagonistfunctional antagonism demonstrated in humans: feeling high reduced by up to 82.8% at 30 mg (Gorbenko et al. 2025); no affinity constant found
  • Blocks or inhibits

The lower the cited value, the closer the target sits to Selonabant: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Selonabant.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Antagonistno measured value cited

    functional antagonism demonstrated in humans: feeling high reduced by up to 82.8% at 30 mg (Gorbenko et al. 2025); no affinity constant found

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of Selonabant, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

Selonabant, first studied for obesity, is being developed under the code ANEB-001 for a different aim: acute cannabinoid intoxication. Gorbenko and colleagues recall that emergency department visits for cannabinoid-related toxicity have increased worldwide as more states have liberalised cannabis policy, with symptoms such as anxiety, panic attacks, tachycardia and psychosis, mainly mediated by CB1 agonism by Δ9-THC. Their phase II trial (randomised, double-blind, placebo-controlled, in healthy adults) combines oral THC (10.5 mg, then 21 mg) with oral selonabant capsules (10, 30, 50 or 100 mg). Versus placebo, selonabant reduced feeling high by up to 82.8 % at 30 mg, increased self-reported alertness by up to 10.8 mm, and reduced postural instability by up to 30.6 % at 30 mg; heart rate was not significantly changed. The product was judged generally safe, with no clinically meaningful change in mood; nausea and vomiting were more frequent at high doses, and the 10-mg dose was both well tolerated and efficacious. The authors conclude that these results support further development for emergency treatment of acute cannabinoid intoxication (Gorbenko et al. 2025). The trial was funded by Anebulo Pharmaceuticals, several of whose shareholders or executives are among the authors.

History

Source
Entirely synthetic compound with no known natural occurrence. It is in clinical development (phase II published in 2025) and is not marketed.

Origin

Research tool

No known biosynthetic pathway: a synthetic molecule. It is an azetidine carboxamide, N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide (name read on PubChem, CID 68902536).

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

Selonabant (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
Selonabant (ANEB-001)
IUPAC name
N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide
Other names
ANEB-001 · ANEB 001 · Selonabant · V-24343

Identifiers

Formula
C₂₂H₂₄ClF₃N₂O₂
CAS
791848-71-0
InChIKey
BNLYOVHLLDBOFZ-LJQANCHMSA-N
SMILES
CC(C)(C)NC(=O)N1CC(O[C@H](c2ccc(Cl)cc2)c2ccccc2C(F)(F)F)C1

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.